VC: Cerimon Pharmaceuticals leads with $70M first round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Creimon
San Francisco

$70M
first round

MPM Capital

The money will be used to expand its product pipeline through innovative partnering transactions and product acquisitions.

Devax
Irvine, CA

$32M
fourth round

InterWest Partners, U.S. Venture Partners

The funding will be used to finance its US IDE clinical study and international marketing of the Axxess drug eluting bifurcation stent.

Surface Logix
Brighton, MA

$32M
third round

Venrock Associates

Surface Logix will use the funds to continue the development of SLx-2101, a potent, long acting PDE5 inhibitor, and to bring new proprietary programs into the clinic.

Marinus Pharmaceuticals
Branford, CT

$29.4M
first round

Domain Associates, Sofinnova Ventures, Canaan Partners

The funds will be used primarily for the in-licensing and development of clinical stage drugs to treat neurological, psychiatric and pain disorders.

TransOral Pharmaceuticals
Corte Madera, CA

$23M
third round

Partners

The money will go to development of their lead products, which will compete in the sleep and migraine therapeutic markets.

Celleration
Eden Prairie, MN

$20.6M
third round

Triathalon Medical Ventures

Celleration is developing MIST Therapy in patients with chronic and hard to heal wounds.

ForteBio
Menlo Park, CA

$17.3M
second

Vertical

The money will assemble a marketing and sales organization in preparation for the launch of ForteBio's first product.

Viral Therapies
San Diego

$8M
second round

MedVenture Associates

The proceeds will initiate further clinical studies of the Extracorporeal Liver Assist Device system.

Molecular Profiling Institute
Phoenix

$7.5M
second round

AmeriPath, Affymetrix, Gen-Probe

The funding will help launch additional molecular tests for breast cancer, prostate cancer, and lymphoma.